Breaking News Instant updates and real-time market news.

PBYI

Puma Biotechnology

$8.89

0.18 (2.07%)

12:32
12/12/19
12/12
12:32
12/12/19
12:32

Puma Biotechnology: plasmaMATCH trial shows neratinib activity in ERBB2 cancer

Puma Biotechnology announced that its collaborators at The Institute of Cancer Research, London, presented results from the cohort of patients in the plasmaMATCH trial treated with Puma's drug neratinib at the 2019 San Antonio Breast Cancer Symposium in San Antonio, Texas. The oral presentation entitled, "Results from the plasmaMATCH trial: A multiple parallel cohort, multi-centre clinical trial of circulating tumour DNA testing to direct targeted therapies in patients with advanced breast cancer," and the poster presentation entitled, "Results from plasmaMATCH trial treatment Cohort B: A phase II trial of neratinib plus fulvestrant in ER positive breast cancer or neratinib alone in ER negative breast cancer in patients with a ERBB2 mutation identified via ctDNA screening" were presented by Professor Nicholas Turner, M.D., Ph.D., Professor of Molecular Oncology at The Institute of Cancer Research and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, who is the principal investigator of the plasmaMATCH trial, and Andrew M. Wardley, M.D., consultant medical oncologist at The Christie NHS Foundation Trust in Manchester, England and Medical Director of the National Institute for Health Research Manchester Clinical Research Facility at The Christie, respectively. The plasmaMATCH trial was funded by Cancer Research UK. Approximately 1,044 patients with advanced breast cancer from approximately 20 sites in the United Kingdom registered for the trial and ctDNA results were available for 1,033 of the patients. The efficacy results from the trial showed that for the 20 efficacy evaluable patients, 5 patients experienced a confirmed objective response, and three further patients had unconfirmed responses. The median duration of response was 5.7 months, and the median progression free survival in this cohort of patients was 5.4 months.

PBYI Puma Biotechnology
$8.89

0.18 (2.07%)

11/07/19
LEHM
11/07/19
NO CHANGE
Target $6
LEHM
Underweight
Puma Biotechnology price target lowered to $6 from $9 at Barclays
Barclays analyst Gena Wang lowered her price target for Puma Biotechnology to $6 from $9 and keeps an Underweight rating on the shares. Puma reported Q3 Nerlynx revenue of $53.6M, below the consensus of $59.0M, and lowered its 2019 guidance for the second time to $205M-$210M from $220M-$240M, Wang tells investors in a research note. The analyst continues to see a limited growth outlook in extended adjuvant setting as well as metastatic HER2+ breast cancer.
11/07/19
RBCM
11/07/19
NO CHANGE
Target $13
RBCM
Sector Perform
Puma Biotechnology price target lowered to $13 from $23 at RBC Capital
RBC Capital analyst Kennen MacKay lowered his price target on Puma Biotechnology to $13 and kept his Sector Perform rating after its Q3 results showed a miss on Nerlynx sales. The analyst warns that the print may reflect lower demand due to dose-reductions, also noting his lowered estimates in late-stage metastatic breast cancer where he sees greater competitive pressure from other HER2+ agents in that setting.
11/08/19
CANT
11/08/19
NO CHANGE
Target $14
CANT
Neutral
Puma Biotechnology price target lowered to $14 from $20 at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young lowered her price target for Puma Biotechnology to $14 from $20 saying she's more cautious on the long-term revenue outlook for Nerlynx following the company's Q3 results. The analyst reiterates a Neutral rating on the shares.
12/06/19
HCWC
12/06/19
INITIATION
Target $15
HCWC
Buy
Puma Biotechnology initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Edward White initiated coverage of Puma Biotechnology with a Buy rating and $15 price target. The analyst believes metastatic breast cancer is a "sizeable opportunity" for the company to capitalize on with Nerlynx. He sees a "promising future" for the drug.

TODAY'S FREE FLY STORIES

HD

Home Depot

$231.90

3.07 (1.34%)

18:06
01/20/20
01/20
18:06
01/20/20
18:06
Periodicals
Mexican trade union suspends strike threat against Home Depot, Reuters says »

A top Mexican trade union…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

UCFC

United Community Financial

$11.56

-0.02 (-0.17%)

, FDEF

First Defiance Financial

$31.12

-0.1 (-0.32%)

18:00
01/20/20
01/20
18:00
01/20/20
18:00
Hot Stocks
First Defiance Financial receives approval for United Community Financial merger »

First Defiance Financial…

UCFC

United Community Financial

$11.56

-0.02 (-0.17%)

FDEF

First Defiance Financial

$31.12

-0.1 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

FDEF

First Defiance Financial

$31.12

-0.1 (-0.32%)

17:56
01/20/20
01/20
17:56
01/20/20
17:56
Earnings
Breaking Earnings news story on First Defiance Financial »

First Defiance Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

T

AT&T

$38.36

0.33 (0.87%)

, CMCSA

Comcast

$47.48

0.62 (1.32%)

17:37
01/20/20
01/20
17:37
01/20/20
17:37
On The Fly
Box Office Battle: 'Bad Boys for Life' wins MLK Jr. weekend with $73M debut »

"Box Office Battle" is…

T

AT&T

$38.36

0.33 (0.87%)

CMCSA

Comcast

$47.48

0.62 (1.32%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$72.48

-0.07 (-0.10%)

LGF.A

Lionsgate

$10.96

-0.32 (-2.84%)

LGF.B

Lionsgate

$10.32

-0.305 (-2.87%)

DIS

Disney

$144.25

-0.85 (-0.59%)

VIACA

ViacomCBS

$43.26

-0.855 (-1.94%)

VIAC

ViacomCBS

$39.48

-0.57 (-1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 29

    Jan

  • 04

    Feb

  • 04

    Feb

  • 06

    Feb

  • 06

    Feb

STIM

Neuronetics

$4.38

-0.01 (-0.23%)

17:00
01/20/20
01/20
17:00
01/20/20
17:00
Recommendations
Neuronetics analyst commentary  »

Correction in Neuronetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCMD

Tactile Systems

$60.76

-2.74 (-4.31%)

16:55
01/20/20
01/20
16:55
01/20/20
16:55
Recommendations
Tactile Systems analyst commentary  »

Lawsuit may drag out into…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFSC

Enterprise Financial

$48.49

0.16 (0.33%)

16:45
01/20/20
01/20
16:45
01/20/20
16:45
Earnings
Enterprise Financial reports Q4 EPS $1.09, consensus $1.09 »

Reports Q4 net interest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

TGP

Teekay LNG

$14.73

-0.26 (-1.73%)

16:33
01/20/20
01/20
16:33
01/20/20
16:33
Hot Stocks
Teekay LNG Partners declares distribution of 19c per common unit »

Teekay GP, the general…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WES

Western Midstream

$20.60

-0.55 (-2.60%)

16:31
01/20/20
01/20
16:31
01/20/20
16:31
Hot Stocks
Western Midstream announces Q4 2019 distribution »

Western Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

CPG

Crescent Point Energy

$4.20

-0.08 (-1.87%)

16:29
01/20/20
01/20
16:29
01/20/20
16:29
Hot Stocks
Crescent Point closes sale of gas infrastructure assets »

Crescent Point announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHSCP

CHS Inc.

$28.85

0.13 (0.45%)

16:26
01/20/20
01/20
16:26
01/20/20
16:26
Hot Stocks
CHS Inc. names Olivia Nelligan as Chief Financial Officer »

CHS Inc. announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMAB

Genmab

$22.73

-0.13 (-0.57%)

, JNJ

Johnson & Johnson

$149.07

0.82 (0.55%)

16:25
01/20/20
01/20
16:25
01/20/20
16:25
Hot Stocks
Genmab announces European Marketing Authorization for DARZALEX »

Genmab A/S (GMAB)…

GMAB

Genmab

$22.73

-0.13 (-0.57%)

JNJ

Johnson & Johnson

$149.07

0.82 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 09

    Mar

  • 17

    Mar

PRPO

Precipio

$2.09

-0.02 (-0.95%)

16:25
01/20/20
01/20
16:25
01/20/20
16:25
Conference/Events
Precipio to host shareholder update conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

TILE

Interface

$17.37

0.23 (1.34%)

16:22
01/20/20
01/20
16:22
01/20/20
16:22
Hot Stocks
Interface names Dan Hendrix as President, CEO »

Interface announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBCP

Independent Bank

$22.51

-0.26 (-1.14%)

16:19
01/20/20
01/20
16:19
01/20/20
16:19
Hot Stocks
Independent Bank announces 11% increase in quarterly cash dividend »

Independent Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 18

    Feb

  • 19

    Feb

JAZZ

Jazz Pharmaceuticals

$151.00

-0.56 (-0.37%)

16:17
01/20/20
01/20
16:17
01/20/20
16:17
Hot Stocks
Jazz Pharmaceuticals receives EU Marketing Authorization for Sunosi »

Jazz Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

AMRN

Amarin

$19.91

-0.15 (-0.75%)

16:13
01/20/20
01/20
16:13
01/20/20
16:13
Recommendations
Amarin analyst commentary at Jefferies »

Amarin remains in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

, SPX

S&P 500

$0.00

(0.00%)

16:09
01/20/20
01/20
16:09
01/20/20
16:09
Periodicals
Macron, Trump declare truce in digital tax dispute, Reuters reports »

French President Emmanuel…

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$68.55

-0.26 (-0.38%)

, HES

Hess Corp.

$69.87

-0.45 (-0.64%)

16:07
01/20/20
01/20
16:07
01/20/20
16:07
Periodicals
Guyana's first oil cargo to be refined by Exxon in the U.S., Reuters reports »

A vessel carrying…

XOM

Exxon Mobil

$68.55

-0.26 (-0.38%)

HES

Hess Corp.

$69.87

-0.45 (-0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 31

    Jan

  • 23

    Mar

TSLA

Tesla

$510.34

-3.065 (-0.60%)

16:04
01/20/20
01/20
16:04
01/20/20
16:04
Periodicals
Tesla rebuffs U.S. safety recall petition, Reuters reports »

Tesla said there was no…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 24

    Feb

  • 23

    Mar

  • 23

    Mar

EADSY

Airbus

$0.00

(0.00%)

16:02
01/20/20
01/20
16:02
01/20/20
16:02
Periodicals
Airbus unit to offer product to help airlines with revenue risk, Reuters says »

A subsidiary of Airbus is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$318.66

3.33 (1.06%)

15:41
01/20/20
01/20
15:41
01/20/20
15:41
Periodicals
Apple CEO says global corporate tax system must be overhauled, Reuters reports »

Baking changes to global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

, GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

15:27
01/20/20
01/20
15:27
01/20/20
15:27
Periodicals
Alphabet calls for 'proportionate approach' to AI regulation, Reuters reports »

Sundar Pichai, the CEO of…

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

, GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

15:24
01/20/20
01/20
15:24
01/20/20
15:24
Periodicals
Alphabet CEO backs temporary ban on facial-recognition, Reuters reports »

The EU's proposal…

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

MSFT

Microsoft

$167.06

0.82 (0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

  • 25

    Feb

BA

Boeing

$324.11

-7.89 (-2.38%)

, AER

AerCap

$62.35

-0.18 (-0.29%)

15:10
01/20/20
01/20
15:10
01/20/20
15:10
Periodicals
AerCap CEO warns against panic discounts for Boeing 737 MAX, Reuters says »

Owners of Boeing's…

BA

Boeing

$324.11

-7.89 (-2.38%)

AER

AerCap

$62.35

-0.18 (-0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 13

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.